D'ALESSIO, Andrea
 Distribuzione geografica
Continente #
AS - Asia 722
NA - Nord America 631
EU - Europa 538
SA - Sud America 97
AF - Africa 51
OC - Oceania 3
Totale 2.042
Nazione #
US - Stati Uniti d'America 597
SG - Singapore 261
RU - Federazione Russa 255
HK - Hong Kong 146
CN - Cina 135
BR - Brasile 86
VN - Vietnam 71
IT - Italia 65
DE - Germania 50
FR - Francia 43
BJ - Benin 37
GB - Regno Unito 30
KR - Corea 24
IN - India 23
AT - Austria 17
CA - Canada 15
JP - Giappone 14
BD - Bangladesh 12
IE - Irlanda 12
MX - Messico 12
NL - Olanda 12
SE - Svezia 9
FI - Finlandia 8
PL - Polonia 8
UA - Ucraina 8
TR - Turchia 6
ES - Italia 5
PK - Pakistan 5
AR - Argentina 4
CO - Colombia 4
CZ - Repubblica Ceca 4
LT - Lituania 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
EG - Egitto 3
IQ - Iraq 3
MA - Marocco 3
AU - Australia 2
BG - Bulgaria 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ID - Indonesia 2
IL - Israele 2
JM - Giamaica 2
NP - Nepal 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
TH - Thailandia 2
UZ - Uzbekistan 2
AZ - Azerbaigian 1
BE - Belgio 1
CR - Costa Rica 1
EC - Ecuador 1
GD - Grenada 1
KZ - Kazakistan 1
LY - Libia 1
MY - Malesia 1
NR - Nauru 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
Totale 2.042
Città #
Hong Kong 146
Singapore 122
San Jose 110
Ashburn 79
Beijing 38
Cotonou 37
Council Bluffs 37
Los Angeles 34
Moscow 27
Ho Chi Minh City 26
Lauterbourg 24
Santa Clara 22
Seoul 22
New York 21
Hanoi 17
Falkenstein 16
São Paulo 16
Nuremberg 13
Tokyo 13
Assago 12
Buffalo 12
Chicago 12
Dublin 12
Denver 11
Clifton 10
Chennai 9
Frankfurt am Main 9
Stockholm 9
Vienna 9
Amsterdam 8
Brooklyn 8
Helsinki 8
Mexico City 8
London 7
Manchester 7
Orem 7
St Louis 7
Warsaw 7
Ankara 6
Boardman 5
Boston 5
Columbus 5
Da Nang 5
Hangzhou 5
Milan 5
Piscataway 5
Poplar 5
Tianjin 5
Toronto 5
Turin 5
Atlanta 4
Mezzomerico 4
Novara 4
Rome 4
Roubaix 4
Belo Horizonte 3
Dallas 3
Florence 3
Houston 3
Johannesburg 3
Montreal 3
Munich 3
Pardubice 3
Suzhou 3
Uberlândia 3
Wuhan 3
Baghdad 2
Bexley 2
Cairo 2
Calimaya 2
Charlotte 2
Cleveland 2
Concord 2
Concórdia 2
Contagem 2
Deiva Marina 2
Delhi 2
Haiphong 2
Hải Dương 2
Kathmandu 2
Louisville 2
Medellín 2
Mumbai 2
New Delhi 2
Paris 2
Phoenix 2
Recife 2
San Francisco 2
Santa Fe 2
Secaucus 2
Shanghai 2
Sydney 2
Tashkent 2
Uzzano 2
Valduggia 2
Vercelli 2
Zurich 2
Aberdeen 1
Agrolândia 1
Algiers 1
Totale 1.171
Nome #
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 118
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 106
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 101
Effective and organ doses in patient undergoing interventional neuroradiology procedures: A multicentre study 100
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 97
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 86
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 84
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 81
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 81
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 79
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 77
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 76
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 73
Cumulative radiation exposure from radiological imaging in patients with Hodgkin and diffuse large b-cell lymphoma not submitted to radiotherapy 73
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma 73
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 73
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 69
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial 69
. Optimisation of protection in the medical exposure of recurrent adult patients due to computed tomography procedures: development of recurrent exposures reference levels. 68
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 68
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 67
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 67
Reply 65
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 58
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study 58
Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer 52
Reply 51
Totale 2.070
Categoria #
all - tutte 10.694
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.694


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024125 30 0 10 7 20 0 14 4 0 3 5 32
2024/2025490 6 2 46 4 5 66 58 41 76 79 32 75
2025/20261.455 61 51 69 166 210 123 205 200 107 91 137 35
Totale 2.070